We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Method Developed for Enriching Trophoblast Population in Samples

By LabMedica International staff writers
Posted on 02 Sep 2019
A recent paper described a technique to increase the proportion of placental trophoblast cells in cervical samples by 700%, which enables individual trophoblasts to be picked out for genetic testing.

Currently, diagnosis of genetic disorders in developing fetuses requires capture of trophoblasts through amniocentesis or chorionic villus sampling, both invasive procedures. More...
Extravillous trophoblasts (EVTs) have the potential to provide the entire fetal genome for prenatal testing. Previous studies have demonstrated the presence of EVTs in the cervical canal and the ability to retrieve a small quantity of these cells by cervical sampling. However, these small quantities of trophoblasts are greatly outnumbered by the population of cervical cells in the sample, making isolation of the trophoblasts difficult.

Investigators at Brown University (Providence, RI, USA) took advantage of differences in morphology between trophoblasts and other cervical cells (trophoblasts are smaller, differ in shape, and have relatively large nuclei) to develop a method to enrich the trophoblast population in a cervical sample through differential settling of the cells in polystyrene wells.

Initially the investigators added small quantities of JEG-3 trophoblast cell line cells into clinical samples from standard Pap tests taken at five to 20 weeks of gestation to determine the optimal workflow. They observed that a four-minute incubation period in the capture wells led to a maximum in JEG-3 cell settling onto the plastic surface with the removal of more than 90% of the cervical cell population, leading to a 700% enrichment in JEG-3 cells.

The investigators then went on to conduct a proof-of-concept study on an imaging and picking platform to demonstrate the ability to pick single trophoblast cells for whole genome amplification. Results showed that the new technique was quick, inexpensive, minimized cell loss, and yielded retrieval of individual trophoblast cells.

"There is a large need for biomedical engineering techniques toward advancing prenatal and women's health," said first author Christina Bailey-Hytholt, a doctoral research student in biomedical engineering at Brown University. "Our work is a step toward more non-invasive prenatal testing options."

The trophoblast enrichment technique was described in the August 20, 2019, online edition of the journal Scientific Reports.

Related Links:
Brown University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.